627 related articles for article (PubMed ID: 29588318)
21. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
22. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
Cohen CJ; Zheng Z; Bray R; Zhao Y; Sherman LA; Rosenberg SA; Morgan RA
J Immunol; 2005 Nov; 175(9):5799-808. PubMed ID: 16237072
[TBL] [Abstract][Full Text] [Related]
23. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
24. Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection.
Albers JJ; Ammon T; Gosmann D; Audehm S; Thoene S; Winter C; Secci R; Wolf A; Stelzl A; Steiger K; Ruland J; Bassermann F; Kupatt C; Anton M; Krackhardt AM
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877233
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
26. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
27. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Peinert S; Prince HM; Guru PM; Kershaw MH; Smyth MJ; Trapani JA; Gambell P; Harrison S; Scott AM; Smyth FE; Darcy PK; Tainton K; Neeson P; Ritchie DS; Hönemann D
Gene Ther; 2010 May; 17(5):678-86. PubMed ID: 20200563
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.
Zhou Q; Schneider IC; Edes I; Honegger A; Bach P; Schönfeld K; Schambach A; Wels WS; Kneissl S; Uckert W; Buchholz CJ
Blood; 2012 Nov; 120(22):4334-42. PubMed ID: 22898597
[TBL] [Abstract][Full Text] [Related]
30. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
31. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
[TBL] [Abstract][Full Text] [Related]
32. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
33. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
Spranger S; Jeremias I; Wilde S; Leisegang M; Stärck L; Mosetter B; Uckert W; Heemskerk MH; Schendel DJ; Frankenberger B
Blood; 2012 Apr; 119(15):3440-9. PubMed ID: 22371883
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
35. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
36. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
38. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
39. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
40. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
